• Neumora Therapeutics is trading at $1.59 (-5.06%) after RBC Capital lowered its price target to $5.00 from $7.00.
  • This downgrade follows the company's previous announcement in mid-June 2026 of navacaprant's failure in two Phase 3 studies for major depressive disorder and a 35% workforce reduction.
  • The stock's current decline reflects continued investor reaction to clinical setbacks and analyst revisions.